Skip to main content

Advertisement

SpringerLink
Log in

Huntington’s disease

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

  • Huntington’s disease is a neurodegenerative disorder inherited in an autosomal dominant fashion that results in involuntary movements, psychiatric symptoms, and cognitive dysfunction. The illness typically begins in midlife and progresses over 15 to 20 years, producing increasing disability. The diagnosis of Huntington’s disease in an individual has implications for family members as well, whose at-risk status may be altered by the diagnosis. Genetic counseling and information about alternative approaches (eg, clinical diagnosis, DNA banking) should be provided and consent obtained before DNA testing in a symptomatic patient. Genetic counseling is essential for predictive testing in asymptomatic at-risk individuals.

  • Although disease-modifying therapy is not yet available, a multidisciplinary approach to both pharmacologic and nonpharmacologic management can improve the motor and psychiatric symptoms of the illness and enhance function and quality of life for patients and their families. There have been few rigorous trials of treatments for Huntington’s disease. The medications discussed in this article have been empirically found to be useful in the management of specific symptoms. Therapy for the movement disorder should focus on those symptoms that specifically limit function. The potential contribution of medication side effects to disability should be periodically reassessed and therapy adjusted as the disease progresses. Psychiatric symptoms are a substantial source of morbidity in this disorder and should be actively treated because they are often quite responsive to appropriate therapy.

  • Both the motor and the psychiatric symptoms can be modified by environmental as well as pharmacologic strategies. Ongoing assessment of the need for adjunctive therapies by means of physical, occupational, and speech therapy is an important component of management, and social work intervention is often necessary to assist with the practical difficulties faced by patients and caregivers. Voluntary organizations are an important source of information and support for professionals caring for patients with Huntington’s disease as well as for patients and their families.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Nance MA: Clinical aspects of CAG repeat diseases. Brain Pathol 1997, 7:881–900. A recent review of the clinical and genetic features of this newly recognized category of diseases.

    PubMed  CAS  Google Scholar 

  2. Nance MA: Huntington disease—another chapter rewritten. Am J Hum Genet 1996, 59:1–6.

    PubMed  CAS  Google Scholar 

  3. Leroi I, Michalon M: Treatment of the psychiatric manifestations of Huntington’s: a review of the literature. Can J Psychiatry 1998, 43(9):933–940. A recent clinically oriented review of the literature.

    PubMed  CAS  Google Scholar 

  4. Schoenfeld M, Myers RN, Cupples LA, et al.: Increased rate of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 1984, 47:1283–1287.

    PubMed  CAS  Google Scholar 

  5. Farrer LA: Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet 1986, 2:305–311.

    Article  Google Scholar 

  6. Almqvist EW, Block M, Brinkman R, et al.: A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999, 64:1293–1304. Large sample size helps allay physicians’ fears about patient suicide after confirmation of carrier status. Good testing protocols and screening are essential to continued success.

    Article  PubMed  CAS  Google Scholar 

  7. Savage CR: Neuropsychology of subcortical dementias. Psychiatr Clin North Am 1997, 20:991–931.

    Article  Google Scholar 

  8. Rothlind JC, Bylsma FW, Peyser C, et al.: Cognitive and motor correlates of everyday functioning in early Huntington’s disease. J Nerv Ment Dis 1993, 181:194–199.

    Article  PubMed  CAS  Google Scholar 

  9. Bamford KA, Caine ED, Kido DK, et al.: A prospective evaluation of cognitive decline in early Huntington’s disease: functional and radiographic correlates. Neurology 1995, 45:1867–1873.

    PubMed  CAS  Google Scholar 

  10. Wichmann T, DeLong MR: Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996, 6:751–758.

    Article  PubMed  CAS  Google Scholar 

  11. Storey E, Beal MF: Neurochemical substrates of rigidity and chorea in Huntington’s disease. Brain 1993, 116:1201–1222.

    Article  PubMed  Google Scholar 

  12. Lauterbach EC, Cummings JL, Duffy J: Neuropsychiatric correlates and treatment of lenticulostriatal diseases. J Neuropsychiatry Clin Neurosci 1998, 10(3):249–266.

    PubMed  CAS  Google Scholar 

  13. Rosenblatt A, Ranen NG, Nance MA, Paulsen JS: A Physician’s Guide to the Management of Huntington’s Disease, edn 2. New York: Huntington’s Disease Society of America; 1999:41. The management of Huntington’s disease is reviewed by a group of experienced clinicians who address the full range of issues encountered by patients and families. Very useful sections on behavioral and environmental strategies for caregivers are included.

    Google Scholar 

  14. Jenson P, Fenge K, Bolwig TG, et al.: Crime in Huntington’s disease: a study of more registered offences among patients, relatives, and controls. J Neurol Neurosurg Psychiatry 1998, 65:467–471. The only systematic look in the literature at crime rates for patients with Huntington’s disease.

    Google Scholar 

  15. Sanberg PR, Fibiger HC, Mark RF: Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust 1981, 1:407–409.

    PubMed  CAS  Google Scholar 

  16. Chase TN: Rational approaches to the pharmacotherapy of chorea. In Basal Ganglia. Edited by Yahr MD. New York: Raven Press; 1976:337–350.

    Google Scholar 

  17. Shale H, Tanner C: Pharmacological options for the management of dyskinesias. Drugs 1996, 52:849–860.

    PubMed  CAS  Google Scholar 

  18. van Vugt JPP, van Hilten BJ, Roos RAC: Hypokinesia in Huntington’s disease. Mov Disord 1996, 11(4):384–388.

    Article  PubMed  Google Scholar 

  19. Richelson E: Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996, 57(suppl 11):4–11.

    PubMed  CAS  Google Scholar 

  20. Casey DE: The relationship of pharmacology to side effects. J Clin Psychiatry 1997, 58(suppl 10):55–62.

    PubMed  CAS  Google Scholar 

  21. Goff DC, Baldessarini RJ: Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993, 13:57–67.

    Article  PubMed  CAS  Google Scholar 

  22. Collaborative Working Group on Clinical Trial Evaluation: Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998, 59(suppl 12):23–27.

    Google Scholar 

  23. Reveley MA, Dursun SM, Andrews H: A comparative trial of use of sulpiride and risperidone in Huntington’s disease: a pilot study. J Psychopharmacol 1996, 10:162–165.

    Article  CAS  Google Scholar 

  24. Dallocchio C, Buffa C, Tinelli C, Mazzarello P: Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999, 19:101–103.

    Article  PubMed  CAS  Google Scholar 

  25. Chouinard G, Jones B, Remington G, et al.: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993, 13:25–40.

    Article  PubMed  CAS  Google Scholar 

  26. Factor SA, Friedman JH: The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997, 12:483–496.

    Article  PubMed  CAS  Google Scholar 

  27. Bonuccelli U, Ceravolo R, Maremmani C, et al.: Clozapine in Huntington’s chorea. Neurology 1994, 44:821–823.

    PubMed  CAS  Google Scholar 

  28. van Vugt JPP, Siesling S, Vergeer M, et al.: Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997, 63:35–39.

    PubMed  Google Scholar 

  29. Ereshefsky L: Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996, 57(suppl 11):12–25.

    PubMed  CAS  Google Scholar 

  30. Leszczyszyn D, Nohria V, Anderson S: Sustained improvement of juvenile Huntington disease with levodopa/carbidopa [abstract]. Mov Disord 1997, 12:846.

    Google Scholar 

  31. Racette BA, Perlmutter JS: Levodopa responsive parkinsonism in an adult with Huntington’s disease. J Neurol Neurosurg Psychiatry 1998, 64:557–579.

    Google Scholar 

  32. Folstein SE, Chase GA, Wahl WE, et al.: Huntington’s disease in Maryland: clinical aspects of racial variation. Am J Hum Genet 1987, 41:168–179.

    PubMed  CAS  Google Scholar 

  33. Burns A, Folstein S, Brandt J, et al.: Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis 1999, 178(1):20–26.

    Google Scholar 

  34. Mendez MF: Huntington’s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 1994, 24(3):189–208.

    Article  PubMed  CAS  Google Scholar 

  35. Silvestri R, Raffaele M, De Domenico P, et al.: Sleep features in Tourette’s syndrome, neuroacanthocytosis and Huntington’s chorea. Neurophysiol Clin 1995, 25(2):66–77.

    Article  PubMed  CAS  Google Scholar 

  36. Aldrich MS: Insomnia in neurological diseases. J Psychosom Res 1993, 17(suppl 1):1–11.

    Google Scholar 

  37. Taylor N, Bramble D: Sleep disturbance and Huntington’s disease [letter]. Br J Psychiatry 1997, 171:393.

    Article  PubMed  CAS  Google Scholar 

  38. Fedoroff JP, Peyser C, Franz ML, et al.: Sexual disorders in Huntington’s disease. J Neuropsychiatry 1994, 6:147–153.

    CAS  Google Scholar 

  39. Rich SS, Ovsiew F: Leuprolide acetate for exhibitionism in Huntington’s disease. Mov Disord 1994, 9(3):353–357.

    Article  PubMed  CAS  Google Scholar 

  40. Ranen NG, Peyser CE, Folstein SE: ECT as a treatment for depression in Huntington’s disease. J Neuropsychiatry 1994, 6(2):154–159.

    CAS  Google Scholar 

  41. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington’s Chorea: Guidelines for the molecular genetics predictive test in Huntington’s disease. Neurology 1994, 44:1533–1536.

    Google Scholar 

  42. Hersch S, Jones R, Koroshetz W, Quaid K: The neurogenetics genie: testing for the Huntington’s disease mutation. Neurology 1994, 44:1369–1373. Discussion of the recommended protocol for genetic testing in Huntington’s disease. Outlines the rationale and reviews the issues that should be considered by all clinicians recommending such testing.

    PubMed  CAS  Google Scholar 

  43. The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group: Laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 1998, 62:1243–1247.

    Article  Google Scholar 

  44. Feigin A: Advances in Huntington’s disease: implications for experimental therapeutics. Curr Opin Neurol 1998, 11:357–362. Review of the clinical implications of recent basic science advances in understanding the molecular pathology of Huntington’s disease.

    Article  PubMed  CAS  Google Scholar 

  45. Rosas HD, Koroshetz WJ, Jenkins BG, et al.: Riluzole therapy in Huntington’s disease (HD). Mov Disord 1999, 14:326–330.

    Article  PubMed  CAS  Google Scholar 

  46. Kieburtz K, Feigin A, McDermott M, et al.: A controlled trial of remacemide hydrochloride in Huntington’s disease. Mov Disord 1996, 11:273–277.

    Article  PubMed  CAS  Google Scholar 

  47. Kieburtz K: Antiglutamate therapies in Huntington’s disease. J Neural Transm Suppl 1999, 55:97–102.

    PubMed  CAS  Google Scholar 

  48. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF: Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol 1997, 41:160–165.

    Article  PubMed  CAS  Google Scholar 

  49. Peyser CE, Folstein M, Chase GA, et al.: Trial of d-alphatocopherol in Huntington’s disease. Am J Psychiatry 1995, 152:1771–1775.

    PubMed  CAS  Google Scholar 

  50. Ranen NG, Peyser CE, Coyle JT, et al.: A controlled trial of idebenone in Huntington’s disease. Mov Disord 1996, 11:549–554.

    Article  PubMed  CAS  Google Scholar 

  51. Shannon KM, Kordower JH: Neural transplantation for Huntington’s disease: experimental rationale and recommendations for clinical trials. Cell Transplant 1996, 5:339–352.

    Article  PubMed  CAS  Google Scholar 

  52. Kopyov OV, Jacques S, Lieberman A, et al.: Safety of intrastriatal neurotransplantation for Huntington’s disease patients. Exp Neurol 1998, 149:97–108.

    Article  PubMed  CAS  Google Scholar 

  53. University of Kansas Department of Neurology Huntington’s disease Web page: http://www.kumc.edu/ hospital/huntingtons/HSGFTrans.html.

  54. Quinn N, Brown R, Craufurd D, et al.: Core Assessment Program for Intracerebral Transplantation in Huntington’s Disease (CAPIT-HD). Mov Disord 1996, 11:143–150.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Huntington’s Disease Program, University of Virginia Health System #394, 22908, Charlottesville, VA, USA

    Barbara A. Haskins MD & Madaline B. Harrison MD

Authors
  1. Barbara A. Haskins MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Madaline B. Harrison MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haskins, B.A., Harrison, M.B. Huntington’s disease. Curr Treat Options Neurol 2, 243–262 (2000). https://doi.org/10.1007/s11940-000-0007-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-000-0007-0

Keywords

Search

Navigation